@Article{,
AUTHOR = {Ewa Lech-Maranda, Jacques Bienvenu, Anne-Sophie Michallet, Roch Houot, Tadeusz Robak, Bertrand Coiffier, Gilles Salles},
TITLE = {Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma},
JOURNAL = {European Cytokine Network},
VOLUME = {17},
YEAR = {2006},
NUMBER = {1},
PAGES = {60--66},
URL = {http://www.techscience.com/ECN/v17n1/66169},
ISSN = {1952-4005},
ABSTRACT = {The aim of the study was to confirm whether plasma levels of interleukin-10 (IL-10) correlate with
the prognosis in diffuse, large B-cell lymphoma (DLBCL) patients. Plasma IL-10 levels were determined at the
time of diagnosis in a group of 157 consecutively treated, DLBCL patients. Of those, 122 patients (78%) had IL-10
plasma levels below the detection limit (< 5 pg/mL) and 35 (22%) above this value. The median value for patients
with detectable IL-10 levels was 35 pg/mL (range, 5 to 2480 pg/mL). Detectable plasma IL-10 levels were
significantly associated with age > 60 years, ECOG performance status ≥ 2, Ann Arbor advanced disease stage,
bulky tumor mass, elevated serum levels of LDH and b2-microglobulin, presence of anemia and low serum
albumin levels as well as the presence of B symptoms. The patients with detectable IL-10 levels had lower
probability of CR achievement (OR = 0.23, 95% CI 0.1-0.5, p = 0.0003). In addition, detectable IL-10 levels were
significantly associated with shorter PFS (OR = 2.5, 95% CI 1.5-4.4, p = 0.001) and OS (OR = 3.0, 95% CI 1.7-5.2,
p = 0.0001). In conclusion, we confirmed in this large group of DLBCL patients that elevated plasma IL-10 levels
correlated with adverse disease features and poor prognosis. The plasma concentration of IL-10 may be a useful
marker for evaluation of disease activity.},
DOI = {}
}